CD47 and neoplasm: The results showed that LSD1 inhibitors combined with anti-mouse CD47/PD-L1 mAb significantly inhibited tumor growth and altered the tumor microenvironment, indicating that LSD1 may contribute to tumor immune escape through the suppression of immune surveillance against tumor cells.